IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) has been given an average rating of “Hold” by the six brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $2.70.
Several research firms have issued reports on IPCI. Maxim Group set a $2.00 price target on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a report on Friday, February 9th. HC Wainwright set a $3.00 price target on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a report on Monday, February 12th. Finally, Zacks Investment Research lowered IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th.
NASDAQ:IPCI opened at $0.60 on Wednesday. IntelliPharmaCeutics Intl has a 52-week low of $0.51 and a 52-week high of $2.92.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last released its quarterly earnings results on Friday, February 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.01). IntelliPharmaCeutics Intl had a negative net margin of 160.89% and a negative return on equity of 2,811.75%. The company had revenue of $1.08 million for the quarter, compared to the consensus estimate of $1.32 million. equities analysts predict that IntelliPharmaCeutics Intl will post -0.1 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Armistice Capital LLC acquired a new position in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,936,000 shares of the company’s stock, valued at approximately $1,549,000. Armistice Capital LLC owned 6.23% of IntelliPharmaCeutics Intl as of its most recent SEC filing. Institutional investors and hedge funds own 9.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: “IntelliPharmaCeutics Intl Inc (IPCI) Receives $2.70 Consensus PT from Brokerages” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/intellipharmaceutics-intl-inc-ipci-receives-2-70-consensus-pt-from-brokerages.html.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.